Growth Metrics

Merck (MRK) Share-based Compensation (2016 - 2026)

Merck has reported Share-based Compensation over the past 18 years, most recently at $185.0 million for Q1 2026.

  • Quarterly Share-based Compensation fell 5.13% to $185.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $810.0 million through Mar 2026, up 3.85% year-over-year, with the annual reading at $820.0 million for FY2025, 7.75% up from the prior year.
  • Share-based Compensation was $185.0 million for Q1 2026 at Merck, down from $205.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $216.0 million in Q2 2025 and troughed at $120.0 million in Q1 2022.
  • The 5-year median for Share-based Compensation is $176.0 million (2024), against an average of $173.6 million.
  • Year-over-year, Share-based Compensation rose 23.36% in 2023 and then decreased 5.13% in 2026.
  • A 5-year view of Share-based Compensation shows it stood at $145.0 million in 2022, then grew by 15.17% to $167.0 million in 2023, then increased by 11.98% to $187.0 million in 2024, then grew by 9.63% to $205.0 million in 2025, then decreased by 9.76% to $185.0 million in 2026.
  • Per Business Quant, the three most recent readings for MRK's Share-based Compensation are $185.0 million (Q1 2026), $205.0 million (Q4 2025), and $204.0 million (Q3 2025).